Role of Positron Emission Tomography/ Computed Tomography (PET/CT) and in Bone Metastases.

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

66 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-11-01

Study Completion Date

2021-12-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this study is to detect bone metastases by PET/CT examination in cancer patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Assessment of the Accuracy of PET/MR in Detection and Monitoring Response of Bone Metastases

NCT04159376

Bone Metastases

UNKNOWN NA

Using FDG-PET/CT to Assess Response of Bone-Dominant Metastatic Breast Cancer, FEATURE Study

NCT04316117

Anatomic Stage IV Breast Cancer AJCC v8 Hormone Receptor Positive Breast Carcinoma Metastatic Breast Carcinoma +1 more

ACTIVE_NOT_RECRUITING PHASE2

Role of FDG PET/CT in Patients With Metastasis of Unknown Origin

NCT06055764

Metastasis

NOT_YET_RECRUITING

FDG PET/CT in Breast Cancer Bone Mets

NCT01996046

Estrogen Receptor Positive Breast Cancer Bone Metastases

ACTIVE_NOT_RECRUITING

Comparison of FDG and FAPI in Patients With Various Types of Cancer

NCT04416165

Tumor, Solid Positron-Emission Tomography Metastasis

RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Bone is a fertile soil for dissemination of metastatic tumor cells which can cause either osteolytic ( destructive) or osteoblastic (sclerotic) or mixed lesions in advanced cancer. Bone metastases are most common throughout the axial skeleton, this leads to major complications referred to as skeletal-related events (SREs), the most frequently are the need for radiotherapy and pathological fractures, associated with increase life morbidity and decrease overall survival.

Seeking accurate image modalities provides definite staging, determining the optimal strategy of treatment and precise evaluation to decrease the burden of complication.

PET/CT is superior than 2-dimensional planar providing a better image quality and enables quantitation of tumor metabolism. Acquisition and fusion of PET with CT also allow for localization and morphologic evaluation of abnormalities, leading to increased specificity. The National Comprehensive Cancer Network (NCCN) guideline recommended PET/CT imaging in cancers with high risk skeletal metastases, PET has advantage than CT in diagnosing osteolytic lesions; but combining PET with CT, increase the detection of osteoblastic lesions.

CT is recommended to evaluate structural integrity in revealing cortical integrity and the extent of structural destruction.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Bone Metastases

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

18F-FDG PET/CT

18F-fludeoxyglucose positron emission tomography/computed tomography

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* patients diagnosed with different types of malignant tumor, suspected or diagnosed to have bone metastases and will do PET/CT examination
* patients diagnosed with different types of malignant tumor, with accidently discovered bone metastases during PET/CT examination.
* patients conscious to provide informed consent.

Exclusion Criteria

* pregnant women.
* patients with blood sugar \> 200 mg/dL.
* patients unable to sleep in a fixed position for 20 minutes.
* severely ill patients who aren't capable of complying with study procedures or comatose patients.

Eligible Sex

ALL

Accepts Healthy Volunteers

No